CSIMarket
 
Atreca inc   (BCEL)
Other Ticker:  
 
 
Price: $0.0850 $-0.01 -5.660%
Day's High: $0.0998 Week Perf: -7.61 %
Day's Low: $ 0.09 30 Day Perf: 11.7 %
Volume (M): 200 52 Wk High: $ 1.26
Volume (M$): $ 17 52 Wk Avg: $0.40
Open: $0.09 52 Wk Low: $0.06



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 39
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -98
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0

Atreca Inc
Atreca Inc. is a biotechnology company based in Redwood City, California. The company specializes in the discovery and development of novel therapeutics using a unique discovery platform called Atreca Engine. This platform enables the identification and generation of antibodies targeting previously inaccessible and understudied regions of the human immune system.

Atreca focuses on developing therapies for various diseases, including cancer, autoimmune disorders, and infectious diseases. Their approach involves studying the immune responses of patients to identify and isolate antibodies that can effectively target specific disease-causing molecules.

By leveraging their proprietary technology, Atreca aims to develop precise and personalized immunotherapies that have the potential to improve patient outcomes. Their goal is to enhance the understanding of the human immune response and use this knowledge to develop innovative treatments that address unmet medical needs.

Overall, Atreca Inc. is dedicated to pioneering the discovery and development of next-generation therapeutics by harnessing the power of the human immune system.


   Company Address: 835 Industrial Road, Suite 400 San Carlos 94070 CA
   Company Phone Number: 595-2595   Stock Exchange / Ticker: NASDAQ BCEL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Contract

Atreca Strikes Lucrative $12.5M Asset Sale Deal with Immunome, Boosting Novel Therapeutic Development

Published Tue, Dec 26 2023 1:30 PM UTC

Atreca Secures Asset Sale Agreement with Immunome, Potentially Landing $12.5M DealCAMPBELL, Calif. - Atreca, Inc., a preeminent biotechnology firm, has announced a groundbreaking agreement to sell a collection of antibody-related assets and materials to Immunome, Inc. The sale, which showcases Atreca's unique discovery platform and its ability to generate novel therapeutics,...

Atreca Inc

Atreca Inc Struggles to Control Costs, Revealing a $36.6 Million Operating Deficit in Q3 2023



During the ongoing reporting cycle of July to September 30, 2023, numerous companies have announced their earnings results. Atreca Inc, a major player in the pharmaceutical industry, recently disclosed an operating deficit of $-36.649 million for the fiscal third quarter of 2023. This report will provide a closer look at the financial performance of Atreca Inc, analyzing its operating deficits and the company's response through workforce reduction. Additionally, we will examine the recent stock performance of Atreca Inc in the market.
Operating Deficit in Fiscal Third Quarter 2023:
In the fiscal third quarter of 2023, Atreca Inc reported an operating deficit of $-36.649 million, a significant increase compared to the operating deficit of $-23.292 million recorded in the same period of 2022. This represents a challenge for the company as it aims to generate lucrative revenue streams in a highly competitive market.

Atreca Inc

Atreca Inc's Stock Takes a Hit as BCEL Makes Significant Progress in Reducing Operating Losses



Following the financial results of the major players in the Pharmaceutical Preparations sector, it is important to take note of the performance of smaller businesses within the industry. In this context, BCEL has recently reported its operating loss for the second quarter of 2023, while Atreca Inc is expected to release its financial earnings in November 2023. Additionally, the context highlights the recent decline in Atreca Inc's stock performance over the past trading days.
BCEL's Financial Results:
BCEL, a rising company in the Major Pharmaceutical Preparations sector, has shown relative improvement in its operating loss. The company declared an operating loss of $-19.75 million for the second quarter of 2023, compared to a higher loss of $-28.03 million in the same quarter of the previous year. This reflects a significant enhancement in the company's operational efficiency within a year. The deficit has further narrowed from $-27.877 million in the second quarter of 2022 to $-19.186 million in the second quarter of 2023. This positive trajectory indicates BCEL's potential to become a successful competitor in the Healthcare sector.

Atreca Inc

Atreca Inc. Reports Operating Shortfall of $-21.531 Million in First Quarter of 2023, Shows Improved Cost-effectiveness Compared to Previous Year

The pharmaceutical industry has long been a crucial player in the global economy. Given the current state of the world, it has become increasingly important to track the performance of major players within this industry. One such player is Atreca Inc., a rising corporation that recently reported its first quarter earnings for 2023.
According to industry researchers, Atreca Inc. has experienced an operating shortfall of $-21.531 million in the first quarter of 2023. This shortfall is due in part to the fact that the company has not yet reported its top-line for the period. However, it is important to note that Atreca Inc. has been operating more cost-effectively than it did in the previous fiscal quarter ending in March 2022, when it experienced an operating shortfall of $-25.67 million.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com